Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could reveal where cancer drugs go in the body

NCT ID NCT07221825

Recruiting now Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tests a new imaging technique called low-count quantitative SPECT (LC-QSPECT) to see how the drug Radium-223 spreads in men with advanced prostate cancer. About 38 men who are already eligible for Radium-223 will get extra scans after their treatment. The goal is to see if this scan can reliably measure drug uptake in tumors and organs, which could help doctors personalize treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Low-count quantitative single-photon emission computed tomography (LC-QSPECT) imaging
What this could lead to
If successful, this imaging method could help doctors see where Radium-223 goes in the body, potentially leading to better personalized treatment for prostate cancer.
What could go wrong
This is a very early feasibility study with only 38 participants. The imaging technique is new and may not provide clear enough results to change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF THE PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF THE PROSTATE PROSTATE CANCER

Contacts and locations

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.